antiVenX  |   Team   |   Venoms & Toxins   |   Technology   |   Investment   |   Contact Us   |    FAQs

Investment in antiVenX today is an investment in a better future. Here are some reasons why...

1. Venomous Snakebites are Serious - You Can Help!  More than 5.5 million people are bitten each year, mostly in rural and tropical regions around the planet, resulting in >138,000 deaths and many more serious health complications, including lifelong neuromuscular dysfunctions and amputations. In 2017 the WHO designated snakebite envenomation as a Category-A Neglected Tropical Disease.

2. Demand for Venom Antidotes is Increasing: The global supply chain of antivenom is currently finite and limited. Market forecasts indicate continuing growth in the need for effective and affordable venom therapies. Targeted small-molecule drug-based treatments, such as those being developed by antiVenX, have already been proven to be effective in several independent laboratory animal studies.
3. State-of-the-Art Technology with Proven Success:  Modern drug discovery and design techniques have enjoyed a remarkable track record of success over the past decade. Nearly all of the drugs currently under development by large pharmaceutical companies in the US and abroad have been borne out of bioinformatics and cheminformatics “mining expeditions”. This trend has been highly successful due to the rapid expansion of large-scale biomolecular databases in recent years, including the Protein DataBank, ZINC and many others. Additionally, intelligent algorithms for mining such databases have become increasingly powerful and efficient. AntiVenX is working on the cusp of this incredible technology and is actively leveraging these revolutionary developments.
4.  Strong Company Team and Mission: At the core of success in any human endeavor are the people who make things happen. AntiVenX recognizes this fundamental truth and has formed a corporate team that is not only technically competent, but also passionate about the company vision and its humanitarian mission.
5.  Reduced Investor Exposure: AntiVenX is minimizing investor risk by initially focusing on validating its current drug discovery R&D efforts so that a robust foundation of technical knowhow, streamlined computational protocols and intellectual property are galvanized to support an enduring market presence in the future. Because of this early technology validation approach, investors should feel confident that the technology is solid and will lead to significant near and long term dividends.
6.  Groundbreaking Technology:  AntiVenX is new and exciting! It is state-of-the-art and promises to improve treatment of envenomation by making available to the world immediate personalized care that is readily available, effective and, most of all, affordable compared to conventional immune-based therapies. 
7.  Reduced Regulatory Burden for Drug Repurposing:  Unlike de novo drug design which can take 5 to 10 years to gain FDA approval, repositioning of previously FDA-approved drugs for treatment of envenomation generally requires only 2 to 3 years and can be accomplished at a fraction of the cost.
8.  Emerging Markets Beyond Human Indications: While antiVenX plans to focus initially on drug-based treatments for humans, we anticipate pursuing the veterinary marketplace as a strong secondary commercial position. The later also shoulders far less regulatory burden and therefore products in this category may come to market earlier than those intended exclusively for human use. Finally, the wider anti-toxin/anti-venom market space, which includes not only dangerous reptiles, but also insects, arachnids, poisonous plants and microorganisms is currently estimated to exceed US$15B annually. Finally, and perhaps most significantly, is the fact that the venom antidote marketplace is not restricted to only those unfortunate people who are actually bitten. It also includes the much larger market space of outdoor enthusiasts, rural workers, farmers and hikers around the globe who would choose to purchase a stable and affordable kit for field treatment, if it were available. In 2017, it was estimated that in the US alone there were nearly 45 million individuals who engaged in hiking activities. Assuming a kit retails for US$95 + taxes, and 25% of hikers made a purchase, the gross estimated income for the US market alone would be >US$1.0 billion.

antiVenX   |   Team   |   Venoms & Toxins   |   Technology   |   Investment   |   Contact Us   |    FAQs